Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice. 18-Month Clinical and 9-Month Angiographic Outcomes

JACC: Cardiovascular Interventions

Volumn 2, Issue 4, 2009, Pages 303-309

  Han, Yaling ^a   Jing, Quanmin ^a   Xu, Bo ^b   Yang, Lixia ^c   Liu, Huiliang ^d   Shang, Xiaoming ^e   Jiang, Tieming ^f   Li, Zhanquan ^g   Zhang, Hua ^h   Li, Hui ⁱ   Qiu, Jian ^j   Liu, Yingfeng ^k   Li, Yi ^a   Chen, Xuezhi ^a   Gao, Runlin ^b  

^a SHENYANG NORTHERN HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

^c KUNMING GENERAL HOSPITAL   (China)

^d GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^e TANGSHAN GONGREN HOSPITAL   (China)

^f MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^g People's Hospital of Liaoning Province   (China)

^h Shanxi Provincial Corps Hospital of Chinese People's Armed Police Forces   (China)

ⁱ Daqing Oilfield General Hospital   (China)

^j GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^k SOUTHERN MEDICAL UNIVERSITY   (China)

more..

Author keywords

biodegradable polymer; coronary heart disease; drug eluting stents; sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYMER; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BIODEGRADABLE IMPLANT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASIA; ASPIRIN; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMERS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; SIROLIMUS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 64749084561     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.12.013     Document Type: Article

References (36)

1. Moses J.W., Leon M.B., Popma J.J., et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., et al., TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
3. Babapulle M.N., Joseph L., Belisle P., et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
4. Liistro F., and Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 86 (2001) 262-264
5. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
6. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of anti-platelet therapy. Lancet 364 (2004) 1519-1521
7. Ong A.T., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
8. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
9. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
10. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
11. Sousa J.E., Costa M.A., Farb A., et al. Images in cardiovascular medicine: vascular healing 4 years after the implantation of sirolimus-eluting stent in humans: a histopathological examination. Circulation 110 (2004) e5-e6
12. Cutlip D.E., Windecker S., Mehran R., et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
13. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
14. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
15. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
16. Suzuki T., Kopia G., Hayashi S., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 (2001) 1188-1193
17. van der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 (1996) 1690-1697
18. Katayama T., Yamamoto T., Iwasaki Y., et al. Two cases of very late stent thrombosis after implantation of a sirolimus-eluting stent presenting as AMI. Int Heart J 48 (2007) 393-397
19. Commandeur S., van Beusekom H.M., and van der Giessen W.J. Polymers, drug release, and drug-eluting stents. J Interv Cardiol 19 (2006) 500-506
20. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
21. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual anti-platelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007) 813-818
22. Han Y., Jing Q., Chen X., et al. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv 72 (2008) 177-183
23. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372 (2008) 1163-1173
24. Morice M.C., Serruys P.W., Sousa J.E., et al., RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
25. Schofer J., Schluter M., Gershlick A.H., et al., E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
26. Schampaert E., Cohen E.A., Schluter M., et al., C-SIRIUS Investigators. The Canadian study of the sirolimus-eluding stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 (2004) 1110-1115
27. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 652-662
28. Lemos P.A., Serruys P.W., van Domburg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 109 (2004) 190-195
29. Urban P., Gershlick A.H., Guagliumi G., et al., e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-CYPHER registry. Circulation 113 (2006) 1434-1441
30. Gao R.L., Xu B., Lu S.Z., et al., CCSR Investigators. Safety and efficacy of the CYPHER select sirolimus-eluting stent in the "real world"-clinical and angiographic results from the China CYPHER Select registry. Int J Cardiol 125 (2008) 339-346
31. Grube E., Sonoda S., Ikeno F., et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109 (2004) 2168-2171
32. Ge J., Qian J., Wang X., et al. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter Cardiovasc Interv 69; (2007) 198-202
33. Wessely R., Kastrati A., Mehilli J., et al. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J 28 (2007) 2720-2725
34. Buszman P., Trznadel S., Milewski K., et al. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry. Catheter Cardiovasc Interv 71 (2008) 51-57
35. Kitahara H., Kobayashi Y., Fujimoto Y., et al. Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation. Circ J 72 (2008) 168-169
36. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356